SRPT, IP.MI, GXO Pick Recap: Wins, Losses, Lessons

Three picks. Three very different outcomes. Sarepta Therapeutics (SRPT) closed as a loss at -11.9%. Interpump Group (IP.MI) closed as a win at +5.1%. GXO Logistics (GXO) remains open, sitting roughly 24% below its 52-week high despite a 35% Q1 earnings beat and raised guidance. Here is what happened, what the data shows now, and what each situation teaches about the gap between thesis and outcome.

SRPT: The Gene Therapy Bet That Didn't Pay

The original thesis on Sarepta Therapeutics was straightforward: a gene therapy platform with a potential FDA catalyst, trading at a forward P/E of 6.1x, which is remarkably cheap for a biotech with a functioning commercial product. The earnings trajectory looked extraordinary, with year-over-year earnings growth of +2,663.8% in the most recent period.

The stock closed at a loss of 11.9%.

What went wrong? Biotech picks live and die on binary events. When the catalyst doesn't land cleanly, or the market interprets regulatory signals differently than the thesis anticipated, even a statistically cheap stock can move sharply against you. At the current price of $16.64, SRPT trades at a market cap of $1.77B. The analyst consensus target sits at $22.00, implying the street still sees meaningful upside from here. The forward P/E of 6.1x remains one of the lowest in the healthcare universe for a company with a commercial gene therapy on the market.

The lesson is not that the thesis was wrong. It's that biotech positions with hard FDA timelines require tighter position sizing than a typical equity pick. The underlying business, revenue aside (YoY revenue is -1.9%, reflecting a product mix shift rather than demand collapse), still generates the kind of earnings growth that most sectors can't touch. The -11.9% close stings, but the fundamental case for SRPT hasn't evaporated. Analysts covering the stock haven't abandoned their targets.

Sarepta also holds a 17% weight in the ACCE Biotech Catalysts index, which reflects a deliberate view that gene therapy remains one of the highest-conviction structural themes in healthcare over the next decade.

IP.MI: Interpump Delivers a Clean Win

Interpump Group (IP.MI) closed at +5.1%. The thesis was a serial acquirer in niche hydraulics, trading at a 20% discount to what the business warranted. That discount compressed, and the position closed in the green.

At the close, IP.MI trades at €35.04 with a trailing P/E of 17.9x and a forward P/E of 15.0x. Revenue growth is modest at +0.6% year-over-year, and earnings growth is essentially flat at +0.8%. This was never a high-growth story. It was a quality compounder at a discount, and that's exactly how it performed.

The analyst target of $45.56 (per the data) suggests the street sees further room to run from current levels. The market cap sits at $3.68B, which keeps Interpump in the mid-cap industrials tier where institutional coverage is thinner and mispricings persist longer.

The key takeaway here: valuation compression picks work when the discount is real and the business is genuinely stable. Interpump's hydraulics franchise is not exciting, but it is defensible. Low revenue volatility, a dividend yield of 1.0%, and a management team with a long acquisition track record made this a lower-variance bet than SRPT. The 5.1% gain reflects that.

GXO: The Thesis Is Intact, the Market Disagrees

GXO Logistics (GXO) is the most interesting of the three because it remains open and the gap between fundamentals and price is widest.

The numbers are not ambiguous. GXO posted a 35% Q1 EPS beat and raised full-year guidance. Revenue grew 10.8% year-over-year. The forward P/E sits at 14.0x, which is low for a contract logistics operator with GXO's scale and customer mix. The analyst consensus target is $70.67 against a current price of $49.05, a gap of roughly 44%.

Yet the stock sits 24% below its 52-week high.

Why? The trailing P/E of 44.0x creates noise for screens that don't look forward. Year-over-year earnings are down 55.5% on a trailing basis, which reflects a one-time drag rather than an operating deterioration. Investors running backward-looking screens see a stock with collapsing earnings and a 44x multiple. Investors running forward-looking analysis see a 14x multiple with accelerating revenue and a guidance raise.

The market cap is $5.67B. For a company that operates at the intersection of e-commerce fulfillment, automation, and outsourced logistics for blue-chip clients, that is a number that deserves scrutiny. GXO's business model benefits from the same secular tailwinds driving warehouse automation spending globally.

The position is open. The thesis has not broken. What's required now is patience while the trailing earnings distortion rolls off and the forward earnings story becomes the dominant narrative.

What These Three Picks Have in Common

All three picks shared one structural feature: a gap between where the market priced the stock and where the underlying business suggested it should trade. That gap closed quickly for IP.MI, hasn't closed yet for GXO, and closed in the wrong direction for SRPT.

The differentiation comes down to catalyst dependency. IP.MI needed no specific event; the discount simply needed time and stability. GXO needs the market to shift from trailing to forward earnings framing, which is a timing question, not a fundamental one. SRPT needed a regulatory event to go a specific way, and that's the highest-variance bet of the three.

Position sizing should reflect that variance hierarchy. A valuation compression play in industrials is not the same risk profile as a gene therapy FDA catalyst play, even if both look cheap on a forward P/E basis.

As of June 5, 2026, GXO at $49.05 with a $70.67 analyst target and a 14x forward multiple remains the most compelling unresolved situation across these three names. The Q1 beat and guidance raise are on the record. The market simply hasn't caught up yet.